cancer immunotherapy by targeting ido1/tdo and their downstream effectors
Clicks: 312
ID: 238661
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
312 views
47 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #141 of 644 articles by views in sudebno-meditsinskaia ekspertiza
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 644 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The tryptophan to kynurenine metabolic pathway is now firmly established as a key regulator of innate and adaptive immunity. A plethora of preclinical models suggests that this immune tolerance pathway - driven by the key and rate-limiting enzymes indoleamine-2,3-dioxygenase and tryptophan-2,3-dioxygenase - is active in cancer immunity, autoimmunity, infection, transplant rejection and allergy. Drugs targeting this pathway, specifically indoleamine-2,3-dioxygenase, are already in clinical trials with the aim at reverting cancer-induced immunosuppression. In the past years there has been an increase in our understanding of the regulation and downstream mediators of tryptophan metabolism, such as the aryl hydrocarbon receptor as a receptor for kynurenine and kynurenic acid. This more detailed understanding will expand our opportunities to interfere with the pathway therapeutically on multiple levels. Here we discuss the perspective of targeting tryptophan metabolism at these different levels based on reviewing recent insight into the regulation of tryptophan metabolism and its downstream effectors.
| Reference Key |
eplatten2015frontierscancer
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Michael ePlatten;Nikolaus evon Knebel Doeberitz;Iris eOezen;Wolfgang eWick;Katharina eOchs |
| Journal | sudebno-meditsinskaia ekspertiza |
| Year | 2015 |
| DOI |
10.3389/fimmu.2014.00673
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.